AVITA Medical, Inc. (RCEL) Form 10-Q — May 14, 2026
AVITA Medical reported Q1 2026 revenue of $19.3 million, a 4% year-over-year increase, driven by Cohealyx and RECELL GO mini adoption. The company narrowed its net loss to $10.6 million from $13.9 million in the prior year, aided by an 11% reduction in operating expenses. The filing includes a going concern warning due to recurring losses and debt obligations, despite securing a $50 million draw on a new $60 million credit facility with Perceptive Advisors. The new debt carries an 11.5% interest rate and strict revenue covenants, including a $68.5 million trailing twelve-month revenue test.
Key figures
- Revenue
- 19251000
- Total Debt
- 50000000
- Revenue Yoy
- 4%
- Total Assets
- 51544000
- Cash Position
- 8309000
- Debt drawn
- 50000000
- Interest rate
- 11.5%
- Shares outstanding
- 30776689
- Debt facility total
- 60000000
- Barda contract value
- 25500000
- Barda expected revenue
- 3970000
- Net proceeds refinancing
- 6000000
Price after filing
Close on the filing date to close N calendar days later (from $4.36). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.